

DAFTAR PUSTAKA

- Andriani, A., Rika, R., Journal, S. S.-S., & 2014, undefined. (2014). Hubungan Kepatuhan Mengonsumsi Anti Retroviral Virus (Arv) dengan Kenaikan Jumlah Cd4 Odha di Lancang Kuning Support Group Pekanbaru. *Neliti.Com*, 2(3), 150–159. <https://www.neliti.com/publications/286523/hubungan-kepatuhan-mengonsumsi-anti-retroviral-virus-arv-dengan-kenaikan-jumlah>
- Bloom, K., van den Berg, F., & Arbuthnot, P. (2021). Self-amplifying RNA vaccines for infectious diseases. *Gene Therapy*, 28(3–4), 117–129. <https://doi.org/10.1038/s41434-020-00204-y>
- Bracaglia. (2017a). Cardiac Extraction from Suckling Rat - HHS Public Access. *Physiology & Behavior*, 176(3), 139–148. <https://doi.org/10.1016/j.coi.2015.05.007.New>
- Bracaglia. (2017b). Cardiac Extraction from Suckling Rat - HHS Public Access. *Physiology & Behavior*, 176(3), 139–148. <https://doi.org/10.1126/scitranslmed.aaz2686.HIV>
- Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Berlanda Scorza, F., Otten, G. R., Yu, D., Mandl, C. W., Mason, P. W., Dormitzer, P. R., Ulmer, J. B., & Geall, A. J. (2015). Self-Amplifying mRNA Vaccines. In *Advances in Genetics* (Vol. 89). Elsevier Ltd. <https://doi.org/10.1016/bs.adgen.2014.10.005>
- Castell-Rodríguez, A., Piñón-Zárate, G., Herrera-Enríquez, M., Jarquín-Yáñez, K., & Medina-Solares, I. (2017). Dendritic Cells: Location, Function, and Clinical Implications. *Biology of Myelomonocytic Cells*, May. <https://doi.org/10.5772/intechopen.68352>
- Cordeiro, A. S., & Alonso, M. J. (2016). Recent advances in vaccine delivery. *Pharmaceutical Patent Analyst*, 5(1), 49–73. <https://doi.org/10.4155/ppa.15.38>
- Crommelin, D. J. A., Sindelar, R. D., & Meibohm, B. (2019). Pharmaceutical biotechnology: Fundamentals and applications. *Pharmaceutical Biotechnology: Fundamentals and Applications*, 1–653. <https://doi.org/10.1007/978-3-030-00710-2>
- De Jong, W., Aerts, J., Allard, S., Brander, C., Buyze, J., Florence, E., Van Gorp, E., Vanham, G., Leal, L., Mothe, B., Thielemans, K., Plana, M., Garcia, F., & Gruters, R. (2019a). Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled,

- doubleblinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy (Trials DOI: 10.1186/s13063. *Trials*, 20(1), 19–20. <https://doi.org/10.1186/s13063-019-3940-0>
- De Jong, W., Aerts, J., Allard, S., Brander, C., Buyze, J., Florence, E., Van Gorp, E., Vanham, G., Leal, L., Mothe, B., Thielemans, K., Plana, M., Garcia, F., & Gruters, R. (2019b). IHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. *Trials*, 20(1), 1–10. <https://doi.org/10.1186/s13063-019-3409-1>
- de Souza, M. S., Ratto-Kim, S., Chuenarom, W., Schuetz, A., Chantakulkij, S., Nuntapinit, B., Valencia-Micolta, A., Thelian, D., Nitayaphan, S., Pitisuttithum, P., Paris, R. M., Kaewkungwal, J., Michael, N. L., Rerks-Ngarm, S., Mathieson, B., Marovich, M., Currier, J. R., & Kim, J. H. (2012). The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope. *The Journal of Immunology*, 188(10), 5166–5176. <https://doi.org/10.4049/jimmunol.1102756>
- Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015). HIV infection. *Nature Reviews Disease Primers*, 1(October). <https://doi.org/10.1038/nrdp.2015.35>
- Derking, R., Ozorowski, G., Sliepen, K., Yasmeen, A., Cupo, A., Torres, J. L., Julien, J. P., Lee, J. H., van Montfort, T., de Taeye, S. W., Connors, M., Burton, D. R., Wilson, I. A., Klasse, P. J., Ward, A. B., Moore, J. P., & Sanders, R. W. (2015). Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. *PLoS Pathogens*, 11(3), 1–22. <https://doi.org/10.1371/journal.ppat.1004767>
- Dey, A. K., Cupo, A., Ozorowski, G., Sharma, V. K., Behrens, A. J., Go, E. P., Ketas, T. J., Yasmeen, A., Klasse, P. J., Sayeed, E., Desaire, H., Crispin, M., Wilson, I. A., Sanders, R. W., Hassell, T., Ward, A. B., & Moore, J. P. (2018). cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. *Biotechnology and Bioengineering*, 115(4), 885–899. <https://doi.org/10.1002/bit.26498>
- Direktur Jenderal P2P. (2021). Laporan Perkembangan HIV AIDS & Penyakit Infeksi Menular Seksual (PIMS) Triwulan I Tahun 2021. *Kementerian Kesehatan RI*,

4247608(021), 613–614. https://siha.kemkes.go.id/portal/perkembangan-kasus-hiv-aids_pims#

Espinar-Buitrago, M., & Muñoz-Fernández, M. A. (2022). New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection. *Frontiers in Immunology*, 12(January), 1–15. <https://doi.org/10.3389/fimmu.2021.719664>

Ford, N., Meintjes, G., Vitoria, M., Greene, G., & Chiller, T. (2017). The evolving role of CD4 cell counts in HIV care. *Current Opinion in HIV and AIDS*, 12(2), 123–128. <https://doi.org/10.1097/COH.0000000000000348>

Fowler, P. R. (1997). Pharmacotherapy: A Pathophysiologic Approach. 3rd Edition. In *The Australian Journal of Hospital Pharmacy* (Vol. 27, Issue 4). <https://doi.org/10.1002/jppr1997274340>

Gandhi, R. T., Kwon, D. S., Macklin, E. A., Shopis, J. R., McLean, A. P., McBrine, N., Flynn, T., Peter, L., Sbrolla, A., Kaufmann, D. E., Porichis, F., Walker, B. D., Bhardwaj, N., Barouch, D. H., & Kavanagh, D. G. (2016). Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: Results of a randomized, placebo-controlled clinical trial. *Journal of Acquired Immune Deficiency Syndromes*, 71(3), 246–253. <https://doi.org/10.1097/QAI.0000000000000852>

Gigantesco, A., & Giuliani, and M. (2011). Quality of life in mental health services with a focus on psychiatric rehabilitation practice. *Ann Ist Super Sanità*, 47(4), 363–372. <https://doi.org/10.4415/ANN>

Golchin, A. (2021). Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility. *Stem Cell Reviews and Reports*, 17(1), 56–62. <https://doi.org/10.1007/s12015-020-10046-1>

Haynes, B. F., & Burton, D. R. (2017). Developing an HIV vaccine. *Science*, 355(6330), 1129–1130. <https://doi.org/10.1126/science.aan0662>

Hoffmann, C., & Kamps, B. S. (2003). *HIV Medicine 2003*. flying publisher.

Hsu, D. C., & O’Connell, R. J. (2017). Progress in HIV vaccine development. *Human Vaccines and Immunotherapeutics*, 13(5), 1018–1030. <https://doi.org/10.1080/21645515.2016.1276138>

- Husada, D. (2020). *Vaksin SARS-CoV-2 : Tinjauan Kepustakaan*. 228–242.
- Iacob, S. A., Iacob, D. G., & Jugulete, G. (2017). Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. *Frontiers in Pharmacology*, 8(NOV). <https://doi.org/10.3389/fphar.2017.00831>
- Ibrahim, K., Kurnia H, Y., Rahayuwati, L., Nurmalisa, B. E., & Rifa'atul Fitri, S. U. (2018). Hubungan antara Fatigue, Jumlah CD4, dan Kadar Hemoglobin pada Pasien yang Terinfeksi Human Immunodeficiency Virus (HIV). *Jurnal Keperawatan Padjadjaran*, 5(3). <https://doi.org/10.24198/jkp.v5i3.649>
- Irmak, D. K., Darıcı, H., & Karaö, E. (2020). *Stemcell Covid*. 11(5), 1174–1190.
- Jenner, E., Figure, S., Figure, S., & Book, V. F. (2012). Vaccine Fact Book. *Vaccine Fact*, 4–10.
- Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021). HIV and Messenger RNA Vaccine. *Cureus*, 13(7), 1–11. <https://doi.org/10.7759/cureus.16197>
- Khan, N., & Geiger, J. D. (2021). Role of viral protein U (Vpu) in HIV-1 infection and pathogenesis. *Viruses*, 13(8). <https://doi.org/10.3390/v13081466>
- Kirchhoff, F. (2016). Encyclopedia of AIDS. *Encyclopedia of AIDS*, January 2013. <https://doi.org/10.1007/978-1-4614-9610-6>
- Kogan, M., & Rappaport, J. (2011). HIV-1 Accessory Protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention. *Retrovirology*, 8, 1–20. <https://doi.org/10.1186/1742-4690-8-25>
- Kulp, D. W., Steichen, J. M., Pauthner, M., Hu, X., Schiffner, T., Liguori, A., Cottrell, C. A., Havenar-Daughton, C., Ozorowski, G., Georgeson, E., Kalyuzhniy, O., Willis, J. R., Kubitz, M., Adachi, Y., Reiss, S. M., Shin, M., De Val, N., Ward, A. B., Crotty, S., ... Schief, W. R. (2017). Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. *Nature Communications*, 8(1). <https://doi.org/10.1038/s41467-017-01549-6>
- Lahariya, C. (2016). Vaccine epidemiology: A review. *Journal of Family Medicine and Primary Care*, 5(1), 7. <https://doi.org/10.4103/2249-4863.184616>

- Leal, L., Guardo, A. C., Moron-Lopez, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., Van Den Ham, H. J., Gruters, R., Andeweg, A., Meirvenne, S. Van, Pich, J., Arnaiz, J. A., Gatell, J. M., Brander, C., Thielemans, K., Martinez-Picado, J., Plana, M., & García, F. (2018). Phase i clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. *Aids*, 32(17), 2533–2545. <https://doi.org/10.1097/QAD.0000000000002026>
- Letvin, N. L. (2005). Progress toward an HIV vaccine. *Annual Review of Medicine*, 56, 213–223. <https://doi.org/10.1146/annurev.med.54.101601.152349>
- Li, Y., Liu, D., Wang, Y., Su, W., Liu, G., & Dong, W. (2021). The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection. *Frontiers in Immunology*, 12(April), 1–12. <https://doi.org/10.3389/fimmu.2021.638573>
- Maartens, G., Celum, C., & Lewin, S. R. (2014). HIV infection: Epidemiology, pathogenesis, treatment, and prevention. *The Lancet*, 384(9939), 258–271. [https://doi.org/10.1016/S0140-6736\(14\)60164-1](https://doi.org/10.1016/S0140-6736(14)60164-1)
- Macri, C., Dumont, C., Johnston, A. P. R., & Mintern, J. D. (2016). Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. *Clinical and Translational Immunology*, 5(3), e66-8. <https://doi.org/10.1038/cti.2016.6>
- Martin-Gayo, E., & Yu, X. G. (2019). Role of dendritic cells in natural immune control of HIV-1 infection. *Frontiers in Immunology*, 10(JUN), 1–9. <https://doi.org/10.3389/fimmu.2019.01306>
- Melo, M., Porter, E., Zhang, Y., Silva, M., Li, N., Dobosh, B., Liguori, A., Skog, P., Landais, E., Menis, S., Sok, D., Nemazee, D., Schief, W. R., Weiss, R., & Irvine, D. J. (2019). Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. *Molecular Therapy*, 27(12), 2080–2090. <https://doi.org/10.1016/j.ymthe.2019.08.007>
- Mohamed, H., Miller, V., Jennings, S. R., Wigdahl, B., & Krebs, F. C. (2020). The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook. *Journal of Immunology Research*, 2020. <https://doi.org/10.1155/2020/9470102>
- Moyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019). Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines

- Delivered as Self-Amplifying mRNA. *Molecular Therapy - Methods and Clinical Development*, 12(March), 32–46. <https://doi.org/10.1016/j.omtm.2018.10.010>
- Mu, Z., Haynes, B. F., & Cain, D. W. (2021). HIV mRNA vaccines—progress and future paths. *Vaccines*, 9(2), 1–22. <https://doi.org/10.3390/vaccines9020134>
- Nadhira, M., Puspitasari, R. L., Moegni, K. F., Rosadi, I., & Rosliana, I. (2018). Profil Peripheral Blood Mononuclear Cells (PBMC) Pasien dengan Berbagai Usia Menggunakan Flow Cytometry di Klinik Hayandra. *JURNAL Al-AZHAR INDONESIA SERI SAINS DAN TEKNOLOGI*, 4(4), 208. <https://doi.org/10.36722/sst.v4i4.312>
- Nath, A. (2010). HIV/AIDS vaccine: An update. *Indian Journal of Community Medicine*, 35(2), 222–225. <https://doi.org/10.4103/0970-0218.66862>
- NCT05001373 @ www.clinicaltrials.gov. (n.d.). <https://www.clinicaltrials.gov/ct2/show/NCT05001373?term=mRNA+Vaccine&cond=HIV+Infections&draw=2&rank=2>
- Ndhlovu, Z. M., Proudfoot, J., Cesa, K., Alvino, D. M., McMullen, A., Vine, S., Stampouloulou, E., Piechocka-Trocha, A., Walker, B. D., & Pereyra, F. (2012). Elite Controllers with Low to Absent Effector CD8 + T Cell Responses Maintain Highly Functional, Broadly Directed Central Memory Responses . *Journal of Virology*, 86(12), 6959–6969. <https://doi.org/10.1128/jvi.00531-12>
- Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., Hoge, S., Stanton, M. G., & Joyal, J. L. (2020). Impact of mRNA chemistry and manufacturing process on innate immune activation. *Science Advances*, 6(26). <https://doi.org/10.1126/sciadv.aaz6893>
- Paisal & Subangkit. (2013). *Strategi Pengembangan Vaksin Dengue*. *Jurnal Biotek Medisiana Indonesia*. 2(2), 43–49.
- Panjiasih Susmiarsih, T. (2019). Kajian DNA Rekombinan pada Vaksin DNA dan Vaksin Subunit Protein. *Majalah Kesehatan Pharmamedika*, 10(2), 108. <https://doi.org/10.33476/mkp.v10i2.730>
- Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines-a new era in vaccinology HHS Public Access. *Nat Rev Drug Discov*, 17(4), 261–279. <https://doi.org/10.1038/nrd.2017.243.mRNA>

- Pierson, T., McArthur, J., & Siliciano, R. F. (2000). Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annual Review of Immunology*, 18, 665–708. <https://doi.org/10.1146/annurev.immunol.18.1.665>
- Popper, S. J., Sarr, A. D., Travers, K. U., Guèye-Ndiaye, A., Mboup, S., Essex, M. E., & Kanki, P. J. (1999). Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. *Journal of Infectious Diseases*, 180(4), 1116–1121. <https://doi.org/10.1086/315010>
- Pourahmad, J., & Salimi, A. (2015). Isolated human peripheral blood mononuclear cell (PBMC), a cost effective tool for predicting immunosuppressive effects of drugs and Xenobiotics. *Iranian Journal of Pharmaceutical Research*, 14(4), 679–980.
- Prakash Sahoo, J., Mishra, P., Samal, K. C., & Sahoo, J. P. (2021). A New HIV Vaccine Heads to Clinical Trials by Moderna's mRNA Technology. *Biotica Research Today*, 3(10), 853–856. <https://doi.org/10.13140/RG.2.2.32653.26081>
- Prasolov, V. S., & Ivanov, D. S. (2000). Retroviral vectors in gene therapy. *Voprosy Meditsinskoi Khimii*, 46(3), 207–225. https://doi.org/10.1007/978-981-13-0481-1_1
- Purwaniati, & Asnawi, A. (2020). *TARGET KERJA OBAT ANTIVIRUS COVID-19 : REVIEW*. VII(2), 30–42.
- Rea, D., Johnson, M. E., Havenga, M. J. E., Melief, C. J. M., & Offringa, R. (2001). Strategies for improved antigen delivery into dendritic cells. *Trends in Molecular Medicine*, 7(3), 91–94. [https://doi.org/10.1016/S1471-4914\(01\)01948-7](https://doi.org/10.1016/S1471-4914(01)01948-7)
- Ringe, R. P., Yasmeen, A., Ozorowski, G., Go, E. P., Pritchard, L. K., Guttman, M., Ketas, T. A., Cottrell, C. A., Wilson, I. A., Sanders, R. W., Cupo, A., Crispin, M., Lee, K. K., Desaire, H., Ward, A. B., Klasse, P. J., & Moore, J. P. (2015). Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. *Journal of Virology*, 89(23), 12189–12210. <https://doi.org/10.1128/jvi.01768-15>
- Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021). mRNA vaccines manufacturing: Challenges and bottlenecks. *Vaccine*, 39(16), 2190–2200. <https://doi.org/10.1016/j.vaccine.2021.03.038>

- Sanders, R. W., Derking, R., Cupo, A., Julien, J. P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., Golabek, M., de los Reyes, K., Ketas, T. J., van Gils, M. J., King, C. R., Wilson, I. A., Ward, A. B., Klasse, P. J., & Moore, J. P. (2013). A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. *PLoS Pathogens*, 9(9). <https://doi.org/10.1371/journal.ppat.1003618>
- Sari, I. P., & Sriwidodo, S. (2020). Perkembangan Teknologi Terkini dalam Mempercepat Produksi Vaksin COVID-19. *Majalah Farmasetika*, 5(5), 204. <https://doi.org/10.24198/mfarmasetika.v5i5.28082>
- Sarkar, A., Bale, S., Behrens, A. J., Kumar, S., Sharma, S. K., De Val, N., Pallesen, J., Irimia, A., Diwanji, D. C., Stanfield, R. L., Ward, A. B., Crispin, M., Wyatt, R. T., & Wilson, I. A. (2018). Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. *Nature Communications*, 9(1). <https://doi.org/10.1038/s41467-018-04272-y>
- Seitz, R. (2016). Human Immunodeficiency Virus (HIV). *Transfusion Medicine and Hemotherapy*, 43(3), 203–222. <https://doi.org/10.1159/000445852>
- Seydoux, E., Wan, Y. H., Feng, J., Wall, A., Aljedani, S., Homad, L. J., MacCamy, A. J., Weidle, C., Gray, M. D., Brumage, L., Taylor, J. J., Pancera, M., Stamatatos, L., & McGuire, A. T. (2021). Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. *Cell Reports*, 35(5), 109084. <https://doi.org/10.1016/j.celrep.2021.109084>
- Sharma, O., Sultan, A. A., Ding, H., & Triggle, C. R. (2020). A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Frontiers in Immunology*, 11(October 2020), 1–17. <https://doi.org/10.3389/fimmu.2020.585354>
- Stuart, E. A., & Dowdy, D. W. (2021). Evidence-based COVID-19 policy-making in schools. *Nature Medicine*, 27(12), 2078–2079. <https://doi.org/10.1038/s41591-021-01585-2>
- Van Gulck, E., Vlieghe, E., Vekemans, M., Van Tendeloo, V. F. I., Van De Velde, A., Smits, E., Anguille, S., Cools, N., Goossens, H., Mertens, L., De Haes, W., Wong, J., Florence, E., Vanham, G., & Berneman, Z. N. (2012). MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. *Aids*, 26(4). <https://doi.org/10.1097/QAD.0b013e32834f33e8>

- Voisset, C., Weiss, R. A., & Griffiths, D. J. (2008). Human RNA “Rumor” Viruses: the Search for Novel Human Retroviruses in Chronic Disease. *Microbiology and Molecular Biology Reviews*, 72(1), 157–196. <https://doi.org/10.1128/mnbr.00033-07>
- Wang, F., Kream, R. M., & Stefano, G. B. (2020). An evidence based perspective on mRNA-SARScov-2 vaccine development. *Medical Science Monitor*, 26, 1–8. <https://doi.org/10.12659/MSM.924700>
- WHO. (2020). *HIV/AIDS* @ www.who.int. <https://www.who.int/es/news-room/fact-sheets/detail/hiv-aids>
- World Health Organization (WHO). (2013). Module 2: types of vaccine and adverse reactions. *WHO Vaccine Safety Basics*, 38–60.
- World Health Organization (WHO). (2020). *How-Do-Vaccines-Work* @ Www.Who.Int. <https://www.who.int/news-room/feature-stories/detail/how-do-vaccines-work?adgroupsurvey=%7Badgroupsurvey%7D&gclid=Cj0KCQiA47GNBhDrARIsA>
- Xue, B., Mizianty, M. J., Kurgan, L., & Uversky, V. N. (2012). Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. *Cellular and Molecular Life Sciences*, 69(8), 1211–1259. <https://doi.org/10.1007/s00018-011-0859-3>
- Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020). *Formulation and Delivery Technologies for mRNA Vaccines*. https://doi.org/10.1007/82_2020_217